期刊文献+

人PD-L1胞外区基因的克隆、原核表达及抗体制备

Cloning,prokaryotic expression of human PD-L1 and preparation of its antibody
暂未订购
导出
摘要 目的克隆人PD-L1胞外区基因并进行原核表达及相应蛋白的抗体制备,为进一步研究PD-1/PD-L1通路及针对该通路进行疾病治疗和药物筛选奠定基础。方法用PCR方法扩增编码人PD-L1胞外区的基因序列,克隆到原核表达载体pET28a(+)中并进行表达,用His抗体为一抗进行Western blotting鉴定并验证结合活性。用纯化的hPD-L1胞外区蛋白作为抗原免疫日本大耳白兔,制备多克隆抗体。通过酶联免疫吸附实验(ELISA)和流式法检测抗体滴度及其特异性。结果原核表达质粒pET28a(+)-hPD-L1成功构建,并可在大肠埃希菌BL21(DE3)中诱导高效表达,得到的hPD-L1胞外区蛋白经SDS-PAGE和Western blotting鉴定正确。用纯化蛋白免疫日本大耳白兔,制备的多克隆抗体具有较强的免疫结合活性,抗体滴度可达105。结论鉴定和纯化了原核表达的hPD-L1蛋白,制备的相应多克隆抗体能够检测真核细胞表达的hPD-L1蛋白,为进一步研究PD-1/PD-L1生物学活性奠定了实验基础。 Objective Programmed death ligand 1 (PD-L1) is an important ligand of programmed death 1 (PD-1). PD-L1 conjugating to PD-1 confers negative signals to activate lymphocytes,resulting in T/B cell anergy and immune supression. It is very important to know how PD-L1/PD-1 signal pathway works. The present study is focused on PD-L1 protein expression and its activity. Objective To express the extracellular region of PD-L1,purify the protein which acts as an immunogen to generate PD-L1 antibody in rabbit,and verify its activity. Methods The prokaryotic expression plasmid pET28a(+) /hPD-L1 was constructed by using molecular technique,and then it was transformed to E. coli BL21 (DE3) to induce protein expression with IPTG. The expressed products were identified by SDS-PAGE and Western blot. The purified recombinant protein was used as the antigen to immunize rabbits for 3 times for preparation of polyclonal antibody. The antiserum specificity and titer of hPD-L1 were detected by ELISA and flow cytometry (FCM). Results The recombinant hPD-L1 extracellular domain protein was expressed and purified. It was a protein with about 30kD molecular weight as analyzed by SDS-PAGE. A high titer antibody (1:105) was obtained by immunizing rabbit with the purified protein. The data of FCM demonstrated that the antiserum had high affinity to PD-L1 expressed on the membrane of PD-L1 transfected cells. Conclusion The purified protein hPD-L1 has been successfully obtained,which possesses a high antigenicity. The prepared polyclonal antibody shows high specificity and titer in immunized rabbits. The preparation of recombinant hPD-L1 and its polyclonal antibody has provided reliable tools for the future study on the biologic activity of PD-1/PD-L1.
出处 《解放军医学杂志》 CAS CSCD 北大核心 2010年第8期997-999,共3页 Medical Journal of Chinese People's Liberation Army
基金 2008年湖北省自然科学基金(ZRY1279)
关键词 基因 PD-L1 基因表达 抗体 gene PD-L1 gene expression antibody
  • 相关文献

参考文献11

  • 1Zhang C, Wu S, Xue X, et al. Anti-tumor immunotherapy by blockade of the PD-1/PD-L1 pathway with recombinant human PD- 1-IgV[J]. Cytotherapy, 2008, 10(7): 711-719.
  • 2Kozako T, Yoshimitsu M, Fujiwara H, et al. PD1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients[J]. Leukemia, 2009, 23(2): 375-382.
  • 3Urbani S, Amadei B, Tola D, et al. Restoration of HCV-speeific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment[J]. Hepatol, 2008, 48(4): 548-558.
  • 4Onlamoon N, Rogers K, Mayne AE, etal. Soluble PD-1 rescues the proliferative response of simian immunodeficiency virus-specific CD4 and CD8 T cells during chronic infection[J]. Immunology, 2008, 124(2) : 277-293.
  • 5Dong H, Chen L B7-H1 pathway and its role in the evasion of tumor irnmunity[J]. J Mol Med, 2003, 81(5): 281-287.
  • 6Iwai Y, Ishida M, Tanaka Y, etal. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PDL1 blockade[J]. Proc Natl Acad Sci USA, 2002, 99 (19): 12293-12297.
  • 7Ohigashi Y, Sho M, Yamada Y, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer[J]. Clin Cancer Res, 2005, 11(8) : 2947-2953.
  • 8Thompson RH, Gillett MD, Cheville JC, et al, Costimulatory B7- H1 in renal cell cardnoma patients: Indicator of tumor aggressiveness and potential therapeutic target[J]. Proc Natl Acad Sci USA, 2004, 101(49): 17174-17179.
  • 9Tao R, Wang L, Han R, etal. Differential effects of B and T lymphocyte attenuator and programmed death-1 on acceptance of partially versufully MHC-mismatched cardiac allografts[J]. J Immunol, 2005, 175(9): 5774-5782.
  • 10Watson MP, George AJ, Larkin DF. Differential effects of costimulatory pathway modulation on corneal allograft survlval[J]. Invest Ophthalmol Vis Sci, 2006, 47(8): 3417-3422.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部